MultiVir Sets IPO Terms Amid Run Of Cancer Biotech Debuts
Cancer-treatment biotech MultiVir Inc. on Thursday set terms for its initial public offering, as it looks to raise up to $74 million amid a number of cancer-focused biotechs debuting on the...To view the full article, register now.
Already a subscriber? Click here to view full article